ChemComm
Communication
Table 4 Kinetic resolution of various dimethyl 1-hydroxyphosphonates (Æ)-7a–k
theoretical calculations clearly show that ts-(R)-7a (for formation
of the (R)-ester) has a higher energy compared with that of
ts-(S)-7a (for formation of the (S)-ester); therefore, the desired
(S)-ester was selectively obtained by the rapid transformation
through the transition state ts-(S)-7a.
In summary, we have developed an efficient method for
preparing chiral a-hydroxyphosphonates in good yields with
high selectivities by the kinetic resolution of the racemic
substrates in the presence of diphenylacetic acid, pivalic anhydride,
and (R)-BTM.
Ester yield/%
(ee/%)
Alcohol yield/%
(ee/%)
Entry
R
s
1
Et (7a)
Ph(CH2)2 (7b)
n-Pr (7c)
i-Pr (7d)
i-Pr
c-Hex (7e)
t-Bu (7f)
t-Bu
51 (95)
48 (98)
53 (94)
27 (95)
51 (91)
43 (98)
4 (96)
46 (89)
49 (95)
50 (91)
46 (99)
52 (94)
55 (73)
50 (85)
53 (87)
41 (>99)
49 (>99)
43 (>99)
67 (28)
47 (93)
52 (76)
96 (3)
47 (83)
46 (>99)
48 (99)
54 (89)
48 (>99)
43 (99)
47 (87)
46 (>99)
225
518
204
51
2a
3
4
5b
6
74
Notes and references
191
53
7
´
1 For a-hydroxyphosphonates: (a) A. Szymanska, M. Szymczak, J. Boryski,
8b
9
43
´
J. Stawinski, A. Kraszewski, G. Collu, G. Sanna, G. Giliberti, R. Loddo
Bn (7g)
243
112
463
203
30
and P. La Colla, Bioorg. Med. Chem., 2006, 14, 1924; (b) J. J. Hale,
W. Neway, S. G. Mills, R. Hajdu, C. A. Keohane, M. Rosenbach,
J. Milligan, G.-J. Shei, G. Chrebet, J. Bergstrom, D. Card, G. C. Koo,
S. L. Koprak, J. J. Jackson, H. Rosen and S. Mandala, Bioorg. Med. Chem.
10
11c
12
13
14c
15
TBDPSOCH2 (7h)
TBDPSOCH2
BnO(CH2)2 (7i)
BocNHCH2 (7j)
BocNHCH2
CbzNH(CH2)2 (7k)
´
Lett., 2004, 14, 3351; (c) P. Nguyen-Ba, N. Turcotte, L. Yuen, J. Bedard,
33
84
`
M. Quimpere and L. Chan, Bioorg. Med. Chem. Lett., 1998, 8, 3561;
(d) T.-H. Chan, Y.-C. Xin and M. von Itzstein, J. Org. Chem., 1997,
62, 3500; (e) J. Heilmann and W. F. Maier, Angew. Chem., Int. Ed. Engl.,
1994, 33, 471; ( f ) T. R. Burke Jr., Z.-H. Li, J. B. Bolen and V. E. Marquez,
J. Med. Chem., 1991, 34, 1577. For peptide analogues: (g) D. V. Patel,
K. Rielly-Gauvin, D. E. Ryono, C. A. Free, W. Lynn Rogers, S. A. Smith,
J. M. DeForrest, R. S. Oehl and E. W. Petrillo Jr., J. Med. Chem., 1995,
38, 4557; (h) B. Stowasser, K.-H. Budt, L. Jian-Qi, A. Peyman and
D. Ruppert, Tetrahedron Lett., 1992, 33, 6625; (i) D. V. Patel, K. Rielly-
Gauvin and D. E. Ryono, Tetrahedron Lett., 1990, 31, 5591;
( j) D. V. Patel, K. Rielly-Gauvin and D. E. Ryono, Tetrahedron Lett.,
1990, 31, 5587. For a-amino phosphonates: (k) R. Hirschmann,
A. B. Smith III, C. M. Taylor, P. A. Benkovic, S. D. Taylor,
K. M. Yager, P. A. Sprengeler and S. J. Benkovic, Science, 1994,
265, 234; (l) P. P. Giannousis and P. A. Bartlett, J. Med. Chem., 1987,
30, 1603.
a
b
7b = 1, 8b = 2a. Reaction conditions: 0.75 eq. of Ph(CH2)2COOH was
used instead of Ph2CHCOOH, and the corresponding 3-phenylpropano-
ates (9d and 9f) were obtained instead of diphenylacetates (8d and 8f).
c
Reaction conditions: 0.5 eq. of Ph2CHCOOH, 0.6 eq. of Piv2O, 1.2 eq.
of i-Pr2NEt.
2 (a) Y. Zhang, C. Yuan and Z. Li, Tetrahedron, 2002, 58, 2973;
`
¨
(b) O. Pamies and J.-E. Backvall, J. Org. Chem., 2003, 68, 4815;
(c) K. Wang, Y. Zhang and C. Yuan, Org. Biomol. Chem., 2003,
1, 3564; (d) A. Woschek, W. Lindner and F. Hammerschmidt, Adv.
Synth. Catal., 2003, 345, 1287.
3 Y. Demizu, A. Moriyama and O. Onomura, Tetrahedron Lett., 2009,
50, 5241.
4 (a) I. Shiina and K. Nakata, Tetrahedron Lett., 2007, 48, 8314;
(b) I. Shiina, K. Nakata, K. Ono, M. Sugimoto and A. Sekiguchi,
Chem.–Eur. J., 2010, 16, 167; (c) K. Nakata, K. Gotoh, K. Ono,
K. Futami and I. Shiina, Org. Lett., 2013, 15, 1170.
5 (a) V. B. Birman and X. Li, Org. Lett., 2006, 8, 1351; (b) V. B. Birman
and L. Guo, Org. Lett., 2006, 8, 4859; (c) X. Li, H. Jiang, E. W. Uffman,
L. Guo, Y. Zhang, X. Yang and V. B. Birman, J. Org. Chem., 2012,
77, 1722.
6 (a) H. Zhou, Q. Xu and P. Chen, Tetrahedron, 2008, 64, 6494;
(b) Q. Xu, H. Zhou, X. Geng and P. Chen, Tetrahedron, 2009,
65, 2232; (c) P. Chen, Y. Zhang, H. Zhou and Q. Xu, Acta Chim.
Sin., 2010, 68, 1431; (d) B. Hu, M. Meng, Z. Wang, W. Du, J. S. Fossey,
X. Hu and W.-P. Deng, J. Am. Chem. Soc., 2010, 132, 17041; (e) B. Hu,
M. Meng, J. S. Fossey, W. Mo, X. Hu and W.-P. Deng, Chem.
Commun., 2011, 47, 10632; ( f ) D. Belmessieri, C. Joannesse,
P. A. Woods, C. MacGregor, C. Jones, C. D. Campbell,
Fig. 2 Calculated transition structures (ts-(S)-7a and ts-(R)-7a) derived from
intermediate I and (S)-7a or (R)-7a.
the g-amino-functionalized substrate (Æ)-7k (R = CbzNH(CH2)2)
with 0.75 equivalents of diphenylacetic acid afforded the
desired a-acyloxyphosphonate (S)-8k with good enantiomeric
excess (entry 15; 53% yield, 87% ee) along with the recovered
enantiomerically pure alcohol (R)-7k (46% yield, >99% ee).
Determination of the transition states involved in the for-
mation of the chiral (S)-ester from dimethyl (S)-1-hydroxypro-
pylphosphonate ((S)-7a) with intermediate I was carried out
using DFT calculations at the B3LYP/6-31G*//B3LYP/6-31G*
level of theory, as previously reported for the KR of 2-hydroxy-
alkanoates.4b Among the several calculated transition states,
the most stable structure (ts-(S)-7a) is depicted in Fig. 2. The
´
C. P. Johnston, N. Duguet, C. Concellon, R. A. Bragg and
A. D. Smith, Org. Biomol. Chem., 2011, 9, 559. See also;
(g) M. Kobayashi and S. Okamoto, Tetrahedron Lett., 2006, 47, 4347.
7 DFT study of the DMAP-catalyzed acetylation: (a) S. Xu, I. Held,
B. Kempf, H. Mayr, W. Steglich and H. Zipse, Chem.–Eur. J., 2005,
11, 4751. The origin of the enantioselectivity in the CF3–PIP-cata-
lyzed KR was also discussed by using DFT calculations: (b) X. Li,
P. Liu, K. N. Houk and V. B. Birman, J. Am. Chem. Soc., 2008,
130, 13836.
8 H. B. Kagan and J. C. Fiaud, Top. Stereochem., 1988, 18, 249.
9 All experimental data were provided in ESI†.
10 K. Nakata, A. Sekiguchi and I. Shiina, Tetrahedron: Asymmetry, 2011,
22, 1610.
c
10702 Chem. Commun., 2013, 49, 10700--10702
This journal is The Royal Society of Chemistry 2013